Evaluating the EAPOC-COPD System

ConditionCOPD
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWomen's College Hospital

About this trial

This study evaluates the implementation and impact of the Evidence-at-the-Point-of-Care Chronic Obstructive Pulmonary Disease (EAPOC-COPD) system, a computerized clinical decision support system designed to improve the quality of COPD care delivered in community pharmacies. Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and healthcare utilization, and significant gaps persist in key evidence-based practices, including symptom and exacerbation risk assessment, appropriate pharmacotherapy, provision of COPD action plans, and referral for specialist care.

The EAPOC-COPD system builds on a previously validated asthma platform and provides pharmacists with guideline-based decision support through a structured patient questionnaire and point-of-care recommendations, including treatment optimization and generation of personalized action plans.

This study will be conducted across six community pharmacies implementing the EAPOC-COPD system as part of a quality improvement initiative. Using a quasi-experimental interrupted time series design, outcomes during a 12-month intervention period will be compared to a 12-month pre-intervention baseline period.

The study will evaluate both implementation outcomes (including system uptake, usability, feasibility, and acceptability among pharmacy teams and patients) and effectiveness outcomes. Effectiveness outcomes include improvements in guideline-based COPD care processes, such as rates of symptom and exacerbation risk assessment, optimization of pharmacotherapy, provision of COPD action plans, and appropriate referral for specialist care.

Results from this study will inform the scalability and broader implementation of pharmacy-based clinical decision support tools to enhance chronic disease management and support the expanding role of pharmacists in delivering evidence-based COPD care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Sequential

Treatments tested in this trial

  • EAPOC-COPD

    Behavioral

    The EAPOC-COPD system consists of: 1) a smart phone / tablet app or Personal Computer-based questionnaire which collects information directly from patients upon prompting; 2) a point-of-care clinical decision support system that wirelessly receives and processes questionnaire data in order to produce a symptom severity/exacerbation risk assessment, medication change recommendation, and COPD action plan, all of which is made available to pharmacy providers electronically. Once approved, the personalized COPD action plan is automatically populated within the patient app/portal, enabling anywhere/anytime access for patients. Patients are also provided with educational resources within their app/portal, designed to improve health literacy, inhaler technique, and adherence to their action plan

Treatment groups

25 Participants
are divided into 1 treatment group
Group A: EAPOC-COPD systemExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Implementation outcomes - System usage

System usage (pharmacy team/patients) is a composite outcome that reflects the different usage metrics available in our system, including nature of visit (virtual vs in-person), specific content accessed, and time required for access/documentation

Time frame
During the 1 year intervention period
2

Implementation outcome - usability

Perceived system usability (pharmacy team members, will be collected by using the 10-item System Usability Scale - SUS

Time frame
During the 1 year intervention period
3

Implementation outcome - system satisfaction

satisfaction with/willingness to continue using the system (pharmacy team/patients), collected by questionnaire

Time frame
During the 1 year intervention period
4

Implementation outcome - Prescription sign-back

Proportion of prescriptions sent to doctors for sign-back that are sent back, will be collected from pharmacy chart system review

Time frame
During the 1 year intervention period

Secondary outcomes

1

Effectiveness outcomes - COPD symptoms are exacerbation risk

the proportion of visits in the intervention compared to baseline period in which patients had COPD symptoms and exacerbation risk assessed, as determined by pharmacy chart review

Time frame
During the 1 year intervention period compared to the year prior
2

Effectiveness outcome - COPD medications adjusted

the proportion of visits in the intervention compared to baseline period in which patients had COPD medications adjusted, as determined by pharmacy chart review

Time frame
During the 1 year intervention period compared to the year prior
3

Effectiveness outcome - action plans created

the proportion of visits in the intervention compared to baseline period in which patients had an action plan created, based on pharmacy chart review

Time frame
During the 1 year intervention period compared to the year prior
4

Effectiveness outcome - specialist referral

The proportion of patients who had a specialist referral made

Time frame
During the 1 year intervention period compared to the year prior

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: